Jubilant Ingrevia Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Growth engines firing, but masked by one segment: Specialty Chemicals grew 15% YoY and Nutrition grew ~10%, yet overall revenue fell because Chemical Intermediates shed ~Rs.1,000 crore over two years, offsetting the new investment-driven growth.
• EBITDA quality is improving fast: Specialty EBITDA jumped ~70% to Rs.422 crore on volume growth and cost savings, while Nutrition EBITDA rose 237% YoY, driven by choline and Niacinamide.
• The CDMO flywheel is spinning: 25+ molecules added to the funnel in FY25, two commercial agro contracts already announced, and the cGMP plant is ramping faster than expected, with management calling it a "very strong flywheel."
• Chemical Intermediates is near a cycle bottom: Excess inventory in paracetamol and agrochemical end-markets is mostly cleared, and management expects both volumes and acetic anhydride pricing to start recovering gradually from next quarter.
• What to watch next quarter: Whether the acetyl cycle actually turns, the pace of the cGMP plant ramp toward 70-80% utilization, and the first revenue from the big CDMO agro contract due by January.

The Two-Speed Portfolio: Growth Engines vs. the Acetyl Drag

• Specialty Chemicals delivered 15% YoY revenue growth in FY25, with volume growth even higher because pricing declined in a couple of sub-segments; net revenue growth in volume terms was 25%.
• Nutrition and Health Solutions EBITDA grew 237% YoY and 17% QoQ, driven by higher choline sales, improved Niacinamide volumes and pricing, and continuous cost optimization.
• Chemical Intermediates is the drag: revenue and EBITDA declined on weak paracetamol and agrochemical demand, which hit acetic anhydride volumes and pricing; lower ethyl acetate prices from intense competition added pressure.
• The math that masks the story: Specialty and Nutrition grew, but Chemical Intermediates revenues fell ~Rs.1,000 crore from FY23 to FY25, absorbing the incremental revenue from new investments and making overall results look muted.
• Exports are a bright spot: exports volume growing significantly across all three parts of Specialty Chemicals, with overall export mix up almost 50% versus last year; diketene derivatives landed a couple of big orders last quarter that will continue through the year.

Deepak Jain: "What we have observed is over the last few quarters there was a stocking of excess inventory in both the segments, but at least based on what we are hearing from our customers and our own analysis suggests that most of the inventory is now cleared up or will get cleared up in the coming quarter and hence we are hoping that we are very close to the bottom of the cycle..."

CDMO: The Flywheel Argument

• Funnel build-out: 25+ molecules added in FY25 across pharma, agrochemical and semiconductor, at various stages from early development to commercial; pharma leads at Phase-2/Phase-3 level.
• Two commercial agro contracts already announced: the larger one commissions by end of calendar year with supplies to the customer latest by January; the smaller one starts supplying this quarter. The big one will have a significant impact in the last quarter of FY26, with the full combined impact of both orders in FY27.
• cGMP plant ramp is ahead of plan: commissioned in January, the Food and Cosmetic Grade Niacinamide and Niacin plant at Bharuch has done more volume than expected in the last three months; management is in discussions with a couple of big customers for long contracts and hopes to reach 70-80% utilization in the next 18 months.
• Semiconductor CDMO: 8-10 molecules in development, half a dozen samples sent; management hopes leads will convert to commercial revenues in the next couple of quarters, though the revenue contribution will start small.
• The structural advantage: core product platforms (pyridine, diketene, acetyl anhydride) where the company has done more work than anyone else in India make it the "first port of call" when customer requirements depend on these chemistries; a 150+ strong R&D team and 120+ CEO-led customer meetings in the year reinforce the BD engine.

Deepak Jain: "We have some core product platforms or chemistries like pyridine or diketene or many other even acetyl anhydride, etc., Whenever customers have a requirement in these chemistries or wherever the KSM is dependent on these chemistries, we are the first port of call."

Margin Trajectory & Cost Levers

• Specialty Chemicals EBITDA margin has moved up on cost optimizations and higher growth in pyridine and diketene derivatives; management sees 22%-plus as visible, and closer to 25% as scale builds.
• Nutrition EBITDA margin hit 16% in the last quarter, within the 16-18% steady-state range management targets; FY25 overall was 14%, still below the FY22 peak year. New high-margin products (high-grade Niacinamide, cosmetic grade, food grade, CCBT, premixes) should add growth and margin.
• Chemical Intermediates steady-state margin is 10-12%, based on the 10-year average; currently below that due to the down cycle.
• Lean 2.0 cost optimization: management intends to deliver Rs.100-150 crore of savings during FY26 itself, with the bulk aggregating into the FY26 P&L and only minor spillover possible.
• Company-level steady-state margin is targeted at more than 17-18% across the three segments; EBITDA growth will "definitely outpace revenue growth" due to the portfolio shift toward Specialty and Nutrition plus the savings initiatives.
• Renewable energy from the O2 Power partnership will cover 50% of Bharuch's energy needs, reducing both Scope 2 emissions and power cost in coming quarters.

Pricing & Cycle Outlook by Segment

• Specialty Chemicals: prices have bottomed out and been stable for 6-8 months; no big possibility of significant price recovery, but some marginal increase is possible.
• Nutrition: feed-grade B3 (Niacinamide) pricing is stable; new high-value segments (high-grade Niacinamide, cosmetic grade, food grade) carry a price benefit and may see marginal upside.
• Chemical Intermediates: at the bottom of the cycle; pricing expected to start going up gradually from next quarter or so, supported by inventory clearance in paracetamol and agrochemical end-markets.
• US tariff impact is contained: per management, only 10% of total sales go to the US, and only 25% of those fall under the additional 10% dutiable items, meaning just 2.5% of overall global sales might be affected; the evolving tariff differential versus Chinese exports is expected to create favorable conditions for both volume and pricing of the US export portfolio.

Shyam Bhartia: "Approximately, 10% of our total sales are in the US and only 25% of those fall under additional 10% dutiable items. This means just 2.5% of our overall global sales might be affected by the US tariff."

Capital Allocation & the Path to Rs.10,000 Crore

• FY26 CAPEX plan: Rs.600 crore of additional investment, including some spillover from FY25, largely funded through internal accruals; projects include multi-purpose plants for Fine Chemicals, Diketene Derivatives, new CDMO projects, and the Human Nutrition and Health Solutions portfolio.
• Pinnacle 345 organic CAPEX run-rate: over the next 3-4 years, management expects to invest at least Rs.600-800 crore every year, totaling Rs.2,000-2,500 crore of additional investment, which it believes can take the company past Rs.10,000 crore organically.
• Incremental revenue from existing assets: ~Rs.1,000 crore of incremental revenue is expected from existing capacity as utilization increases, which management hopes to achieve in the next year or so.
• Agro CDMO CAPEX for the two announced orders is progressing on schedule and will add to Specialty Chemicals revenue and margins in coming quarters.
• Dividend: the Board recommended a final dividend of 250% (Rs.2.5 per share) for FY25.

Guidance & Commitments

Key Metrics